An HIV-killing condom could be available to buy within months, after it was given the go-ahead by key regulatory body.
The condom’s antiviral VivaGel, developed by Australian bio-tech firm Starpharma, effectively deactivated 99.9 percent of HIV, herpes and human papilloma virus in trials.
And, after being given a receipt of Conformity of Assessment Certification by the Australian Therapeutic Good Administration, the product is likely to be on shelves soon.
Peter Carroll, the president and general manager of the sexual wellness global business unit for Ansell – who are working in partnership with Starpharma – says consumers can expect a ‘ground-breaking new sexual health’ product.
‘Ansell looks forward to rolling out its marketing and sales campaign to support the launch of Life Styles Dual Protect over the coming months with the first product expected to be available on shelves soon,’ he said.
STIs are on the rise in Australia, where the number newly-diagnosed HIV infections was 70 per cent higher than the number in 1999, when cases were at their lowest.
It is hoped that the VivaGel condom will halt the rise in HIV and other STIs, while also reducing the risk of pregnancy.
No comments:
Post a Comment